Harbin Pharmaceutical Group Co Ltd Reports Half-Year Financial Results

On August 23, 2025, Harbin Pharmaceutical Group Co Ltd (600664), a healthcare company listed on the Shanghai Stock Exchange, released its financial report for the first half of 2025. The company reported a net profit of 2.60 billion CNH, marking a year-over-year decline of 24.37%.

Revenue and Profit Analysis

The company’s total operating revenue for the period was 81.25 billion CNH, a slight decrease of 0.21% compared to the previous year. The operating costs amounted to 59.27 billion CNH, down by 2.88%, while other expenses totaled 17.97 billion CNH, a decrease of 6.36%. After accounting for operating costs and various expenses, the attributable net profit stood at 2.60 billion CNH, reflecting a 24.37% decrease from the previous year.

Asset and Cash Flow Overview

As of the end of the reporting period, the company’s total assets were valued at 140.28 billion CNH, with accounts receivable amounting to 44.79 billion CNH. The net cash flow from operating activities was -1.41 billion CNH, while cash received from sales of goods and services was 81.77 billion CNH.

Financial Health and Performance

According to an analysis by the Tianhua Finance Diagnosis Model, Harbin Pharmaceutical Group has maintained a generally good financial condition over the past five years. The company exhibits strong cash flow and operational capabilities, with good growth, debt repayment, and profitability.

The company has six notable financial highlights:

  • Return on Assets: The average net asset return rate is 10.59%, placing it in the industry’s top tier.
  • Revenue Growth: The average revenue growth rate is 8.95%, ranking it among the industry leaders.
  • Asset Growth: The average net asset growth rate is 11.18%, also in the industry’s top tier.
  • Inventory Turnover: The average inventory turnover rate is 6.11 times per year, indicating strong inventory liquidation capability.
  • Total Asset Turnover: The average total asset turnover rate is 1.14 times per year, reflecting high operational efficiency.
  • Cash Conversion: The average cash conversion rate for main business operations is 101.99%, showing strong revenue liquidation capability.

Overall, Harbin Pharmaceutical Group’s financial condition is rated at 3.63 out of 5, ranking it among the top companies in the chemical pharmaceutical industry, which comprises 159 companies.

Financial Ratings

  • Asset Quality: 0.53 (previous) to 0.91 (current), ranked 131st, considered poor.
  • Cash Flow: 3.36 (previous) to 4.12 (current), ranked 29th, considered ample.
  • Operational Capability: 4.87 (previous) to 4.94 (current), ranked 43rd, considered excellent.
  • Growth Capability: 2.80 (previous) to 3.68 (current), ranked 43rd, considered strong.
  • Debt Repayment Capability: 3.30 (previous) to 3.65 (current), ranked 44th, considered strong.
  • Profitability: 2.45 (previous) to 3.46 (current), ranked 50th, considered good.
  • Overall Score: 2.99 (previous) to 3.63 (current), ranked 18th, considered good.

Additional Information

The Tianhua Finance Diagnosis Model evaluates companies based on their latest and historical financial data and industry conditions. The financial score ranges from 0 to 5, with higher scores indicating better financial health and greater long-term investment value. The model’s insights are based on AI algorithms and are for reference only, not predictions of future financial conditions. Investors should exercise caution and assume responsibility for their investment decisions.

For more detailed stock diagnosis information, please refer to the company’s official announcements and financial reports.